The P63 Immunohistochemistry (IHC) test, also known as the p63, is a vital diagnostic tool performed on tissue samples. The p63 protein, belonging to the p53 protein family, plays a pivotal role in the development and maintenance of various epithelial tissues within the body. Detecting abnormalities in its expression is crucial for identifying potential cancerous conditions.
The p63 IHC marker employs specific antibodies designed to bind exclusively to the p63 protein, facilitating its precise detection in tissue samples. This technique is especially beneficial for diagnosing squamous cell carcinomas, enabling a clear distinction from other types of cancers. The test's reliability and accuracy make it an essential component in pathology practices, contributing significantly to the understanding and diagnosis of various malignancies.
Test NameIHC - P63
Sample TypeTissue
Preparations RequiredNo specific preparation is needed for this test.
Report Time3 days
Pathologists often refer to p63 IHC pathology outlines to interpret and analyze the test results, ensuring thorough comprehension of the cellular and molecular changes associated with abnormal p63 expression. For quality assurance, a p63 IHC control is employed to validate the test's accuracy and reliability. Having a well-defined immunohistochemical p63 protocol is crucial for standardizing the testing process across different laboratories.
Researchers and healthcare professionals may also utilize a p63 IHC positive control to validate the positivity of the test, ensuring that accurate and reproducible results are obtained. The commercial intent of the P63 IHC test, offered by Sprint Diagnostics, lies in its role as a dependable diagnostic tool. This advanced test, available at a Diagnostics centre near you, contributes significantly to advancements in cancer research, patient care, and overall pathology practices.
Home Sample Collection Process
1
Book your convenient slot
2
Sample Collection by Phlebotomist
3
Reporting of the sample at lab
4
Download Reports
Frequently Asked Questions
The P63 IHC test plays a crucial role in diagnosing various cancers, particularly squamous cell
carcinomas. By detecting the presence of p63, the test aids in the differentiation of these cancers from
others, providing critical insights for treatment planning.
No, fasting is not necessary for this test as it's performed on tissue samples, typically obtained
through a biopsy or surgical procedure.
No specific preparation is required. A healthcare provider usually collects the tissue sample during a
biopsy or surgical procedure.
This test detects the presence or absence of the p63 protein in tissue samples. An abnormal expression of
this protein can be indicative of certain types of cancers.
As the test is performed on tissue samples, the main precautions relate to the biopsy or surgical
procedure used to obtain the sample.
There are no specific medication restrictions before this test. However, always inform your doctor about
any medications you're taking before any biopsy or surgical procedure.
Login / Signup
